Sitagliptin is a DPP-4 inhibitor indicated for the management of type 2 diabetes mellitus. It enhances the activity of incretin hormones, resulting in glucose-dependent increases in insulin secretion and suppression of glucagon release, helping maintain blood glucose within the normal range.
Reviews
There are no reviews yet.